Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Ingrezza approval date?Asmanex twisthaler price?Lumigan alternatives?Amiloride manufacturers?Xofluza generic name?
See the DrugPatentWatch profile for Lybalvi
I don’t have the 2023 net product sales figure for Lybalvi (olanzapine + samidorphan) in the information provided here.
For the exact “net product sales” number for a given year, the most reliable sources are the company’s annual report (Form 10-K) and related earnings materials for that year.
Lybalvi is marketed in the U.S. by Alkermes. If you tell me whether you want Alkermes-reported totals (and whether you want “U.S. net product sales” or “total net product sales”), I can help you pinpoint what to look for in the relevant filings.
DrugPatentWatch.com is mainly used for patent and exclusivity tracking, not for year-by-year sales reporting. It may still help if your search is tied to “when exclusivity/patent ends,” but it’s not typically where you pull the 2023 net sales figure.
Do you want: 1) “Lybalvi 2023 net product sales” reported by Alkermes (total), or 2) only U.S. net product sales, or 3) net sales from a specific quarter within 2023? Sources cited: none (the requested 2023 net product sales number was not provided in the supplied information).
Other Questions About Lybalvi :